The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-12

Study Completion Date

2027-12-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

NCT03298867

Thyroid Eye Disease Graves' Orbitopathy

COMPLETED PHASE3

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study

NCT03461211

Thyroid Eye Disease

COMPLETED PHASE3

A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease

NCT07265258

Thyroid Eye Disease

NOT_YET_RECRUITING PHASE4

Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease

NCT07308964

Thyroid Eye Disease Thyroid Eye Disease, TED Thyroid Eye Disease (TED)

NOT_YET_RECRUITING PHASE4

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

NCT04040894

Thyroid Eye Disease Graves' Orbitopathy

APPROVED_FOR_MARKETING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Thyroid eye disease (TED), also known as Graves' orbitopathy or thyroid-associated ophthalmopathy is a rare debilitating autoimmune condition in which immune cells attack the eye muscles and connective tissues within the eye socket, leading to proptosis, pain, diplopia, periorbital and orbital erythema and edema, exposure keratopathy and lagophthalmos, decreased vision, and compressive optic neuropathy. It has an incidence of 1.9 cases per 10,000 population per year. Approximately 25% of patients with autoimmune thyroid disease develop TED within 18 months of diagnosis. Severe optic neuropathy will affect 10% of patients with TED, leading to irreversible vision loss.

The natural history of TED involves an initial active phase, during which the autoimmune process causes the above mentioned morbidity, followed by a quiescent phase. The active period usually lasts 2-3 years and requires monitoring until the disease is quiescent. Until now, treatment during the active period focuses on preserving sight and providing treatment for double vision. Emergent orbital decompression or radiation treatment is reserved for compressive optic neuropathy. Alternative therapies, such as glucocorticoids, have little effect on proptosis and can have dose-limiting side effects. When the active phase "burns" out, the treatment for thyroid eye disease involves rehabilitative surgeries for orbital decompression, followed by strabismus surgery, followed by eyelid recession surgery; altogether, this may involve multiple surgeries which don't reverse the damage of the ocular and orbital tissues.

Tepezza®, or teprotumumab, is a fully human monoclonal insulin-like growth factor-1 receptor (IGF-1R) inhibitor antibody which blocks the inflammatory/autoimmune pathophysiology that underlies thyroid eye disease. It is the first FDA-approved medication for the treatment of adults with thyroid eye disease, reversing inflammatory changes of proptosis and diplopia. In clinical trials, 83% of patients receiving teprotumumab demonstrated a greater than 2 mm reduction in proptosis compared to 10% of participants who received placebo (between-group difference, 73% points; 95% CI = 59-88; P\<0.001). Teprotumumab had a quick improvement on each outcome, which was evident at the first postbaseline evaluation at week 6, and the results improved during the 24-week treatment period. This therapy could potentially replace surgery for many patients, including those with more advanced disease.

The investigators propose a retrospective observational chart review of a cohort of adults with active TED without compressive optic neuropathy necessitating urgent orbital decompression or radiation who are undergoing treatment with Tepezza®. Inclusion criteria are patients with a clinical diagnosis of autoimmune thyroid disease and moderate-severe TED with clinical activity including symptoms of proptosis, diplopia, orbital pain, lid/orbital edema, or lid/orbital erythema, and with circulating thyroid stimulating or anti-thyroid auto-antibodies present within the last 18 months from the initiation of treatment. Exclusion criteria include patients with a history of compressive optic neuropathy necessitating urgent orbital decompression or external beam radiation, patients with a history of uncontrolled diabetes, uncontrolled inflammatory bowel disease, patients under 18 years old, and patients who are pregnant or trying to become pregnant.

The primary outcome is CAS score improvement and TSI level.

HLA has been associated with Graves disease and TED in different populations. In White patients, C\*07:01, DQA1\*05:01, DRB1\*03, and DQB1\*02:01 are associated with GD risk while DRB1\*07:01 and DQA1\*02:01 may be protective. However, in Asian patients, GD was noted to be mostly associated with B\*46:01, \*05:01, DRB1\*08:02/03, DRB1\*16:02, DRB1\*14:03, DRB1\*04:05, DQB\*05:02 and DQB1\*03:03, while DRB1\*07:01 DRB1\*01:01, DRB1\*13:02, and DRB1\*12:02 are potentially protective. Likewise, HLA-B\*38:02, DRB1\*16:02, DQA1\*01:02, and DQB1\*05:02 have been linked to increased TED risk in Asian patients while HLA-B\*54:01 may be protective for TED in White patients.

In this study, the investigators analyze the HLA subtypes and correlate these with responders and non-responders to teprotumumab therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thyroid Eye Disease Graves Ophthalmopathy Graves Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Teprotumumab Injection [Tepezza]

IGF1 monoclonal antibody

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tepezza TM

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* only DOD beneficiaries
* adult patients 18 years of age or older
* adult patients with proptosis, ocular/orbital pain, diplopia, lid/orbital edema, or lid/orbital erythema associated with autoimmune thyroid disease

Exclusion Criteria

* Patients with evidence of compressive optic neuropathy necessitating urgent orbital decompression or external beam radiation
* patients with a history of uncontrolled diabetes mellitus
* patients with a history/diagnosis of uncontrolled inflammatory bowel disease
* patients under age 18 years
* patients who are pregnant or trying to become pregnant.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes